Global HIV Diagnostics Market By Overview
HIV Diagnostics Market accounted for US$ 3.6 billion in 2020 and is estimated to be US$ 10.07 billion by 2030 and is anticipated to register a CAGR of 10.8%.
Human Immunodeficiency virus (HIV) causes retroviral infectious disease such as Acquired Immunodeficiency Syndrome (AIDS). HIV attacks on the body immune system specifically CD4 cells (T cells), which helps the immune system to prevent infections. HIV generally spreads through infectious blood or imparting needles, and sexual interactions. The HIV diagnosis can be done by performing viral load test, saliva test, and blood test. For most accurate results, enzyme linked immunosorbent assay (ELISA) test followed by western blot method is one of the efficient and popular method for detection of HIV. Human Immunodeficiency virus (HIV) causes Acquired Immunodeficiency Syndrome (AIDS).For the diagnosis of HIV blood test, saliva test, urine test and viral load test are carried out. HIV is most commonly diagnosed by doing a urine test and blood test. But, enzyme linked immunosorbent assay (ELISA) test followed by Western Bloat Method is one of the most efficient methods for obtaining the results.
Global HIV Diagnostics Market By Dynamics
HIV diagnostics market is driven by major factor such as increase in prevalence of HIV/AIDS across the globe. For instance, according to UNAIDS, in year 2017 there were approximately 36.9 million people worldwide living with HIV/AIDS. Various governmental initiatives by countries to generate the awareness of HIV in people have driven the growth of the HIV Diagnostic Market. For instance, according to U.S. department of health & human services, in May 2017, the federal government supports a range of services that are essential for reducing risk behavior. Thus, making it possible for people living with HIV receive medical care and treatment. Rise in number of infectious blood transfusions and blood donations causes the incidences of HIV/ AIDS, which in turn fosters the HIV diagnostics market. In addition, literacy among people regarding transmission mode, and unsafe sex are some among the major factors which increases incidence of HIV is turn expected to propel HIV diagnostics market. Moreover, benefits of point-of-care instruments and kits in which patients can be diagnosed even outside the laboratory, and advancements in disease diagnostic tests are expected to drive the HIV diagnostics market over the forecast period. . For instance, in 2017, researchers at University of Illinois, Urbana Campaign, developed a portable spectral analyzer based on ELISA assay that enables a smartphone to perform lab grade medical diagnostic tests, which usually requires expensive instruments. However, stringent government regulations and unfavorable reimbursement policies are factors which restrain growth of the HIV diagnostics market.
Global HIV Diagnostics Market By Segmentation
The HIV diagnosis market has been segmented on the basis of test type, product, end user, and region.
On the basis of product, the HIV diagnosis market has been categorized into consumables, instrument, and software & services. On the basis of test type, the HIV diagnosis market has been segmented into antibody tests, viral load tests, CD4 count tests, test for early infant diagnosis, and tests for viral identification. The antibody test segment has been further subdivided into HIV-1 screening tests, HIV-1 confirmatory tests, and HIV-2 & group O diagnostic tests. Based on end user, the HIV diagnosis market has been segmented into diagnostic laboratories, hospitals, blood banks, home care settings, and others.
Regional Insights:
HIV Diagnostics Market accounted for US$ 3.6 billion in 2020 and is estimated to be US$ 10.07 billion by 2030 and is anticipated to register a CAGR of 10.8%.
For detailed understanding of market dynamics, the HIV diagnostics market is analyzed across key regions viz North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. Each of these regions is analyzed on the basis of market findings across major countries in these regions for a macro-level understanding of the HIV diagnostics market. The North America accounts for major share in terms of revenue in HIV diagnostics market. The main factors responsible for this are supportive government initiatives and funding for increasing HIV diagnosis procedures. According to the Centers for Disease Control and Prevention (CDC)in 2017, 38,739 people received an HIV diagnosis test in the U.S. Asia-Pacific expected to be lucrative market for HIV diagnostics, due to increasing patients suffering from HIV/AIDS and increasing awareness about HIV diagnostics among the population in this region. In the Middle East and Africa region, South Africa is an emerging market owing to increasing awareness and presence of a large number of infected people. For instance, according to U.S. department of health & human services, in 2017, there were 19.6 million people living with HIV (53%) in eastern and southern
Report Scope:
|
Attribute |
Details |
|
Base year for estimation |
2020 |
|
Forecast period |
2020 – 2029 |
|
Market representation |
Revenue in USD Million & CAGR from 2020 – 2029 |
|
Market Segmentation |
By Test type - Antibody Tests (HIV-1 Screening Tests, HIV-1 Confirmatory Tests, and HIV-2 & Group O Diagnostic Tests), Viral Load Tests, CD4 Count Tests, Tests for Early Infant Diagnosis, and Tests for Viral Identification By Product – Consumables, Instrument, and Software & Services By End-User – Diagnostic Laboratories, Hospitals, Blood Banks, Home Care Settings, and Others |
|
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
|
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at , regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the HIV Diagnostics Market report based on Product, Test Type, End-user and Region.
HIV Diagnostics Market, By Region:
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
Global HIV Diagnostics Market By Key Players
The key players operating in the HIV diagnostics market includes Abbott Healthcare, BD Biosciences, Roche Diagnostics, Zyomyx Incorporation, Merck & Company Incorporation, Bristol –Myres Squibb, Janssen Therapeutic, Hologic Incorporation, Chembio Diagnostic Systems, and Alere Incorporation.
Global HIV Diagnostics Market By Key Issues Addressed
Recent Development:
- In November 2022, Abbott has launched ‘Panbio™’ HIV Self Test’ at retail which will increase access to faster, reliable and discrete testing at home. Newly launched self test kit is a finger-stick blood test which helps in detecting HIV-1 and HIV-2 antibodies within 15 to 20 minutes. ‘Panbio™’ HIV Self Test’ is reliable and highly accurate.
- In August 2022, Molbio Diagnostics has launched new ‘Truenat’ RT-PCR test for HIV. Newly launched ‘Truenat’ is a portable, battery operated, and IoT enabled Real Time PCR platform which provides result in less than one hour.
- In April 2021, Altona Diagnostics has launched new ‘AltoStar HIV RT-PCR Kit 1.5’ which is based on RT-PCR technology and used for detection & quantification of HIV-1 in human EDTA plasma. Newly launched test kit will help in allowing amplification of separate regions of HIV-1 genome for monitoring HIV infected patients.
Global HIV Diagnostics Market By Company Profile
- Abbott Healthcare
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- BD Biosciences
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Roche Diagnostics
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Zyomyx Incorporation
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Merck & Company Incorporation
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Bristol –Myres Squibb
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Janssen Therapeutic
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Hologic Incorporation
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Chembio Diagnostic Systems
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Alere Incorporation
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
Global HIV Diagnostics Market By Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Preview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Product
- Market Snippet, By Test Type
- Market Snippet, By End User
- Market Snippet, By Region
- Opportunity Map Analysis
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- Product Launch
- Impact Analysis
- PEST Analysis
- Porter’s Analysis
- Market Dynamics
- Market Segmentation, By Product, 2019 – 2029, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2019 — 2029
- Y-o-Y Growth Analysis (%), 2019 – 2029
- Segment Trends
- Consumables
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Instrument
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Software & Services
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Overview
- Market Segmentation, By Test Type, 2019 – 2029, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2019 — 2029
- Y-o-Y Growth Analysis (%), 2019 – 2029
- Segment Trends
- Antibody Tests
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- HIV-1 Screening Tests
- HIV-1 Confirmatory Tests
- HIV-2 and Group O Diagnostic Tests
- Viral Load Tests
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- CD4 Count Tests
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Tests for Early Infant Diagnosis
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Tests for Viral Identification
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Overview
- Market Segmentation, By End User, 2019 – 2029, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2019 — 2029
- Y-o-Y Growth Analysis (%), 2019 – 2029
- Segment Trends
- Diagnostic Laboratories
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Hospitals
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Blood Banks
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Home Care Settings
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Others
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Overview
- Global Market, By Region, 2019 – 2029, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2019 — 2029
- Y-o-Y Growth Analysis (%), 2019 – 2029
- Regional Trends
- North America
- Market Size and Forecast (US$ Mn), By Product, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Test Type, 2019 – 2029
- Market Size and Forecast (US$ Mn), By End-User, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Country, 2019 – 2029
- U.S.
- Canada
- Europe
- Market Size and Forecast (US$ Mn), By Product, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Test Type, 2019 – 2029
- Market Size and Forecast (US$ Mn), By End-User, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Country, 2019 – 2029
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- Market Size and Forecast (US$ Mn), By Product, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Test Type, 2019 – 2029
- Market Size and Forecast (US$ Mn), By End-User, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Country, 2019 – 2029
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast (US$ Mn), By Product, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Test Type, 2019 – 2029
- Market Size and Forecast (US$ Mn), By End-User, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Country, 2019 – 2029
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Market Size and Forecast (US$ Mn), By Product, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Test Type, 2019 – 2029
- Market Size and Forecast (US$ Mn), By End-User, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Country, 2019 – 2029
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Overview
- Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Cepheid
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Becton Dickinson and Company
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Roche Diagnostics
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Zyomyx Incorporation
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Merck KGaA
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Bristol–Myres Squibb
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Johnson & Johnson Services, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Hologic Incorporation
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Chembio Diagnostic Systems
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Abbott
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Cepheid
- Analyst Views
- Section
- Research Methodology
- About Us
- Contact
FAQs
The global HIV diagnostic market is segmented based on product, test type, end user, and region.
Rising prevalence of HIV/AIDS across the globe is the major factor driving growth of the global market.
The North America accounts for major share in terms of revenue in global HIV diagnostics market. The main factors responsible for this are supportive government initiatives and funding for increasing HIV diagnosis procedures.
The key players operating in the Global HIV diagnostics market includes Abbott Healthcare, BD Biosciences, Roche Diagnostics, Zyomyx Incorporation, Merck & Company Incorporation, Bristol –Myres Squibb, Janssen Therapeutic, Hologic Incorporation, Chembio Diagnostic Systems, and Alere Incorporation.